Summary of 14 patients with response SD or more (n = 59 evaluable patients)
| Tumor sites at entry | |||||
|---|---|---|---|---|---|
| Stratum | MIBG score | CT longest dimension | Bone marrow | Overall response (site responses) | # Courses response maintained |
| 2 | 3 | 0 | Negative | PR | 11 |
| 2 | 11 | 0 | Positivea(<5%) | SD (SD on MIBG; CR in BM) | 15 |
| 2 | 15 | 0 | Negative | SD | 45+b |
| 2 | 7 (all sites radiated C1) | 0 | Positive (<5%) | SD (MIBG sites resolved, not evaluable since radiated) | 35 (5 courses compassionate) |
| 1 | 1 | 4 cm | Negative | SD | 30+c |
| 1 | 1 | 5 cm | Negative | SD | 30+d |
| 1 | 25 | 10.3 cm | Negative | SD | 24 |
| 1 | 0 | 4 cm | Negative | SD | 15 |
| 2 | 11 | 0 | Negative | SD | 9 |
| 1 | 15 | 10.9 | Negative | SD | 7 |
| 2 | 1 | 0 | Positive (<5–10%) | SD (CR at MIBG avid bone site; not evaluable since radiated) | 7 |
| 2 | 11 | 0 | Positive (<5%) | SD | 7 |
| 1 | 1 | 6 cm | Negative | SD | 5 |
| 1 | 2 | 8.5 cm | Negative | SD | 4 |
↵aBM slides not reviewed; reports were reviewed.
↵bCentrally reviewed C1–C20; 15 compassionate courses. Alive with SD and no further therapy 13 months off fenretinide.
↵cCompleted C30 with SD; achieved CR on compassionate fenretinide 25 months later; last confirmed 50 months post-C30; alive on fenretinide 53 months post-C30.
↵dPost-C30 given 13-cis-retinoic acid for 3 months. Alive 57 months post-C30. BM = bone marrow; C = course.